Predicine

Predicine develops a next-generation liquid biopsy platform for precision cancer therapies, using its proprietary GeneRADAR technology to simultaneously profile cell-free DNA and RNA from a single tube of blood. The platform offers molecular profiling assays including PredicineATLAS for 600 genes, PredicineCARE for 200 genes, PredicineRNA for fusions and splicing, PredicineBEACON for MRD detection, and PredicineHEME. Predicine also introduces urine-based liquid biopsy for painless cancer detection, with more robust variant detection in genitourinary cancers. Founded in 2015 and headquartered in Hayward, California, the company has raised approximately $41.3M in Series B funding. Predicine differentiates itself through dual DNA and RNA analysis, low input requirements from as little as 0.4mL of plasma, CLIA and CAP certified facilities in California and Shanghai, and partnerships supporting biomarker-driven clinical trials for leading biopharmaceutical companies.